Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Rinatabart sesutecan - ProfoundBio

Next Previous
Drug Profile

Rinatabart sesutecan - ProfoundBio

Alternative Names: GEN-1184; PRO-1184; Rina-S- ProfoundBio; Rinatabart sesutecan-ProfoundBio

Latest Information Update: 06 Feb 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator
  • Developer Genmab; ProfoundBio
  • Class Alkaloids; Antineoplastics; Camptothecins; Drug conjugates; Immunoconjugates; Monoclonal antibodies
  • Mechanism of Action DNA topoisomerase I inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Endometrial cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Phase II Non-small cell lung cancer
  • Phase I/II Solid tumours

Most Recent Events

  • 30 Jan 2026 Phase-II clinical trials in Non-small cell lung cancer (Second-line therapy or greater, Late-stage disease, Metastatic disease) in Japan (IV) (NCT07288177)
  • 30 Jan 2026 Phase-II clinical trials in Non-small cell lung cancer (Second-line therapy or greater, Late-stage disease, Metastatic disease) in USA (IV) (NCT07288177)
  • 07 Jan 2026 Phase-III clinical trials in Fallopian tube cancer (Combination therapy, Recurrent, Second-line therapy or greater) in Japan (IV) (NCT07225270)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top